Morphic (MORF) Stock Price, News & Analysis

Company Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $56.99 to $56.99
• 50-Day Range: $55.74 to $56.99
• 52-Week Range: $19.34 to $57.00
• Volume: 400 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $2.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MORF Stock Analysis - Frequently Asked Questions

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) announced its earnings results on Thursday, July, 25th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.19.

When did Morphic IPO?

Morphic (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

What other stocks do shareholders of Morphic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), SPDR S&P 500 ETF Trust (SPY), Advanced Micro Devices (AMD), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/25/2024
• Today: 8/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MORF
• CIK: 1679363
• Web: www.morphictx.com
• Phone: (781) 996-0955
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$152.10 million
• Net Margins: N/A
• Pretax Margin: -29,119.96%
• Return on Equity: -26.62%
• Return on Assets: -25.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.13
• Quick Ratio: 24.13

Sales & Book Value

• Annual Sales: $520 thousand
• Price / Sales: 5,490.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.31 per share
• Price / Book: 4.63

Miscellaneous

• Outstanding Shares: 50,094,000
• Free Float: 37,270,000
• Market Cap: $2.85 billion
• Optionable: Optionable
• Beta: 1.49